{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T13:43:58Z","timestamp":1793713438439,"version":"4.6.1"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"This study was supported by the China National Key Research and Development","award":["Program No. 2020YFC2009000"],"award-info":[{"award-number":["Program No. 2020YFC2009000"]}]},{"name":"This study was supported by the China National Key Research and Development","award":["Program No. 2020YFC2009000"],"award-info":[{"award-number":["Program No. 2020YFC2009000"]}]},{"name":"This study was supported by the China National Key Research and Development","award":["Program No. 2020YFC2009000"],"award-info":[{"award-number":["Program No. 2020YFC2009000"]}]},{"name":"This study was supported by the China National Key Research and Development","award":["Program No. 2020YFC2009000"],"award-info":[{"award-number":["Program No. 2020YFC2009000"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-87286-z","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T12:12:54Z","timestamp":1737547974000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Mechanistic insights into pachymic acid\u2019s action on triple-negative breast Cancer through TOP2A targeting"],"prefix":"10.1038","volume":"15","author":[{"given":"Ming","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhui","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"key":"87286_CR1","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.5858\/134.7.e48","volume":"134","author":"ME Hammond","year":"2010","unstructured":"Hammond, M. E. et al. American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer (unabridged version). Arch. Pathol. Lab. Med. 134, e48\u201372. https:\/\/doi.org\/10.5858\/134.7.e48 (2010).","journal-title":"Arch. Pathol. Lab. Med."},{"key":"87286_CR2","doi-asserted-by":"publisher","first-page":"e071674","DOI":"10.1136\/bmj-2022-071674","volume":"381","author":"RA Leon-Ferre","year":"2023","unstructured":"Leon-Ferre, R. A. & Goetz, M. P. Advances in systemic therapies for triple negative breast cancer. Bmj 381, e071674. https:\/\/doi.org\/10.1136\/bmj-2022-071674 (2023).","journal-title":"Bmj"},{"key":"87286_CR3","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1186\/s12885-015-1121-4","volume":"15","author":"SY Bae","year":"2015","unstructured":"Bae, S. Y. et al. Poor prognosis of single hormone receptor- positive breast cancer: similar outcome as triple-negative breast cancer. BMC Cancer. 15, 138. https:\/\/doi.org\/10.1186\/s12885-015-1121-4 (2015).","journal-title":"BMC Cancer"},{"key":"87286_CR4","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1038\/s41571-021-00565-2","volume":"19","author":"G Bianchini","year":"2022","unstructured":"Bianchini, G., De Angelis, C., Licata, L. & Gianni, L. Treatment landscape of triple-negative breast cancer - expanded options, evolving needs. Nat. Rev. Clin. Oncol. 19, 91\u2013113. https:\/\/doi.org\/10.1038\/s41571-021-00565-2 (2022).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"87286_CR5","doi-asserted-by":"publisher","first-page":"115545","DOI":"10.1016\/j.bcp.2023.115545","volume":"212","author":"AM Karim","year":"2023","unstructured":"Karim, A. M. et al. Triple-negative breast cancer: epidemiology, molecular mechanisms, and modern vaccine-based treatment strategies. Biochem. Pharmacol. 212, 115545. https:\/\/doi.org\/10.1016\/j.bcp.2023.115545 (2023).","journal-title":"Biochem. Pharmacol."},{"key":"87286_CR6","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/s0140-6736(13)62422-8","volume":"384","author":"P Cortazar","year":"2014","unstructured":"Cortazar, P. et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet 384, 164\u2013172. https:\/\/doi.org\/10.1016\/s0140-6736(13)62422-8 (2014).","journal-title":"Lancet"},{"key":"87286_CR7","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel, R. L., Miller, K. D., Fuchs, H. E. & Jemal, A. Cancer statistics, 2022. CA Cancer J. Clin. 72, 7\u201333. https:\/\/doi.org\/10.3322\/caac.21708 (2022).","journal-title":"CA Cancer J. Clin."},{"key":"87286_CR8","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1186\/s13058-020-01296-5","volume":"22","author":"L Yin","year":"2020","unstructured":"Yin, L., Duan, J. J., Bian, X. W. & Yu, S. C. Triple-negative breast cancer molecular subtyping and treatment progress. Breast Cancer Res. 22, 61. https:\/\/doi.org\/10.1186\/s13058-020-01296-5 (2020).","journal-title":"Breast Cancer Res."},{"key":"87286_CR9","doi-asserted-by":"publisher","unstructured":"van den Ende, N. S. et al. Triple-negative breast Cancer and predictive markers of response to Neoadjuvant Chemotherapy: a systematic review. Int. J. Mol. Sci. 24 https:\/\/doi.org\/10.3390\/ijms24032969 (2023).","DOI":"10.3390\/ijms24032969"},{"key":"87286_CR10","doi-asserted-by":"publisher","first-page":"771839","DOI":"10.3389\/fphar.2021.771839","volume":"12","author":"Z Zhang","year":"2021","unstructured":"Zhang, Z. et al. The clinical value of Chemotherapy Combined with Capecitabine in Triple-negative breast Cancer-A Meta-analysis. Front. Pharmacol. 12, 771839. https:\/\/doi.org\/10.3389\/fphar.2021.771839 (2021).","journal-title":"Front. Pharmacol."},{"key":"87286_CR11","doi-asserted-by":"publisher","first-page":"102459","DOI":"10.1016\/j.ctrv.2022.102459","volume":"110","author":"RC Bonadio","year":"2022","unstructured":"Bonadio, R. C. et al. Management of patients with early-stage triple-negative breast cancer following pembrolizumab-based neoadjuvant therapy: what are the evidences? Cancer Treat. Rev. 110, 102459. https:\/\/doi.org\/10.1016\/j.ctrv.2022.102459 (2022).","journal-title":"Cancer Treat. Rev."},{"key":"87286_CR12","doi-asserted-by":"publisher","first-page":"1271420","DOI":"10.3389\/fbioe.2023.1271420","volume":"11","author":"W Zeng","year":"2023","unstructured":"Zeng, W. et al. Advances in Doxorubicin-based nano-drug delivery system in triple negative breast cancer. Front. Bioeng. Biotechnol. 11, 1271420. https:\/\/doi.org\/10.3389\/fbioe.2023.1271420 (2023).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"87286_CR13","doi-asserted-by":"publisher","first-page":"S87","DOI":"10.37765\/ajmc.2021.88626","volume":"27","author":"NG Adel","year":"2021","unstructured":"Adel, N. G. Current treatment landscape and emerging therapies for metastatic triple-negative breast cancer. Am. J. Manag Care. 27, S87\u2013s96. https:\/\/doi.org\/10.37765\/ajmc.2021.88626 (2021).","journal-title":"Am. J. Manag Care"},{"key":"87286_CR14","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1186\/s13045-023-01497-3","volume":"16","author":"S Zhu","year":"2023","unstructured":"Zhu, S. et al. Recent advances in targeted strategies for triple-negative breast cancer. J. Hematol. Oncol. 16, 100. https:\/\/doi.org\/10.1186\/s13045-023-01497-3 (2023).","journal-title":"J. Hematol. Oncol."},{"key":"87286_CR15","doi-asserted-by":"publisher","first-page":"479","DOI":"10.6004\/jnccn.2020.7554","volume":"18","author":"TE Keenan","year":"2020","unstructured":"Keenan, T. E. & Tolaney, S. M. Role of Immunotherapy in Triple-negative breast Cancer. J. Natl. Compr. Canc Netw. 18, 479\u2013489. https:\/\/doi.org\/10.6004\/jnccn.2020.7554 (2020).","journal-title":"J. Natl. Compr. Canc Netw."},{"key":"87286_CR16","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1038\/nrclinonc.2016.66","volume":"13","author":"G Bianchini","year":"2016","unstructured":"Bianchini, G., Balko, J. M., Mayer, I. A., Sanders, M. E. & Gianni, L. Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease. Nat. Rev. Clin. Oncol. 13, 674\u2013690. https:\/\/doi.org\/10.1038\/nrclinonc.2016.66 (2016).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"87286_CR17","doi-asserted-by":"publisher","first-page":"109570","DOI":"10.1016\/j.biopha.2019.109570","volume":"121","author":"Y Wang","year":"2020","unstructured":"Wang, Y. et al. Antitumor effects of immunity-enhancing traditional Chinese medicine. Biomed. Pharmacother. 121, 109570. https:\/\/doi.org\/10.1016\/j.biopha.2019.109570 (2020).","journal-title":"Biomed. Pharmacother"},{"key":"87286_CR18","doi-asserted-by":"publisher","first-page":"1577","DOI":"10.1142\/s0192415x20500780","volume":"48","author":"S Wang","year":"2020","unstructured":"Wang, S., Long, S., Deng, Z. & Wu, W. Positive role of Chinese Herbal Medicine in Cancer Immune Regulation. Am. J. Chin. Med. 48, 1577\u20131592. https:\/\/doi.org\/10.1142\/s0192415x20500780 (2020).","journal-title":"Am. J. Chin. Med."},{"key":"87286_CR19","doi-asserted-by":"publisher","first-page":"1087755","DOI":"10.3389\/fimmu.2023.1087755","volume":"14","author":"X Feng","year":"2023","unstructured":"Feng, X., Li, Z., Guo, W. & Hu, Y. The effects of traditional Chinese medicine and dietary compounds on digestive cancer immunotherapy and gut microbiota modulation: a review. Front. Immunol. 14, 1087755. https:\/\/doi.org\/10.3389\/fimmu.2023.1087755 (2023).","journal-title":"Front. Immunol."},{"key":"87286_CR20","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1142\/s0192415x2450040x","volume":"52","author":"Q Wu","year":"2024","unstructured":"Wu, Q., Yan, H. & Kang, Z. A. Review of traditional Chinese Medicine for Triple negative breast Cancer and the pharmacological mechanisms. Am. J. Chin. Med. 52, 987\u20131011. https:\/\/doi.org\/10.1142\/s0192415x2450040x (2024).","journal-title":"Am. J. Chin. Med."},{"key":"87286_CR21","doi-asserted-by":"publisher","first-page":"547","DOI":"10.3892\/etm.2022.11484","volume":"24","author":"C Wei","year":"2022","unstructured":"Wei, C. et al. Pharmacological profiles and therapeutic applications of pachymic acid (review). Exp. Ther. Med. 24, 547. https:\/\/doi.org\/10.3892\/etm.2022.11484 (2022).","journal-title":"Exp. Ther. Med."},{"key":"87286_CR22","doi-asserted-by":"publisher","first-page":"1877","DOI":"10.7314\/apjcp.2012.13.5.1877","volume":"13","author":"R Hong","year":"2012","unstructured":"Hong, R., Shen, M. H., Xie, X. H. & Ruan, S. M. Inhibition of breast cancer metastasis via PITPNM3 by pachymic acid. Asian Pac. J. Cancer Prev. 13, 1877\u20131880. https:\/\/doi.org\/10.7314\/apjcp.2012.13.5.1877 (2012).","journal-title":"Asian Pac. J. Cancer Prev."},{"key":"87286_CR23","doi-asserted-by":"publisher","first-page":"609","DOI":"10.1007\/s10549-010-0929-5","volume":"126","author":"H Ling","year":"2011","unstructured":"Ling, H., Zhang, Y., Ng, K. Y. & Chew, E. H. Pachymic acid impairs breast cancer cell invasion by suppressing nuclear factor-\u03baB-dependent matrix metalloproteinase-9 expression. Breast Cancer Res. Treat. 126, 609\u2013620. https:\/\/doi.org\/10.1007\/s10549-010-0929-5 (2011).","journal-title":"Breast Cancer Res. Treat."},{"key":"87286_CR24","doi-asserted-by":"publisher","first-page":"136","DOI":"10.1016\/j.tips.2021.11.004","volume":"43","author":"C Nogales","year":"2022","unstructured":"Nogales, C. et al. Network pharmacology: curing causal mechanisms instead of treating symptoms. Trends Pharmacol. Sci. 43, 136\u2013150. https:\/\/doi.org\/10.1016\/j.tips.2021.11.004 (2022).","journal-title":"Trends Pharmacol. Sci."},{"key":"87286_CR25","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/s1875-5364(23)60429-7","volume":"21","author":"X Li","year":"2023","unstructured":"Li, X. et al. Network pharmacology approaches for research of Traditional Chinese Medicines. Chin. J. Nat. Med. 21, 323\u2013332. https:\/\/doi.org\/10.1016\/s1875-5364(23)60429-7 (2023).","journal-title":"Chin. J. Nat. Med."},{"key":"87286_CR26","doi-asserted-by":"publisher","first-page":"102425","DOI":"10.1016\/j.coph.2023.102425","volume":"74","author":"F Lazzara","year":"2024","unstructured":"Lazzara, F. et al. Integrating network pharmacology: the next-generation approach in ocular drug discovery. Curr. Opin. Pharmacol. 74, 102425. https:\/\/doi.org\/10.1016\/j.coph.2023.102425 (2024).","journal-title":"Curr. Opin. Pharmacol."},{"key":"87286_CR27","doi-asserted-by":"publisher","unstructured":"Zhang, P. et al. Network pharmacology: towards the artificial intelligence-based precision traditional Chinese medicine. Brief. Bioinform. 25 https:\/\/doi.org\/10.1093\/bib\/bbad518 (2023).","DOI":"10.1093\/bib\/bbad518"},{"key":"87286_CR28","doi-asserted-by":"publisher","first-page":"W357","DOI":"10.1093\/nar\/gkz382","volume":"47","author":"A Daina","year":"2019","unstructured":"Daina, A., Michielin, O. & Zoete, V. SwissTargetPrediction: updated data and new features for efficient prediction of protein targets of small molecules. Nucleic Acids Res. 47, W357\u2013w364. https:\/\/doi.org\/10.1093\/nar\/gkz382 (2019).","journal-title":"Nucleic Acids Res."},{"key":"87286_CR29","doi-asserted-by":"publisher","first-page":"D1197","DOI":"10.1093\/nar\/gkaa1063","volume":"49","author":"S Fang","year":"2021","unstructured":"Fang, S. et al. HERB: a high-throughput experiment- and reference-guided database of traditional Chinese medicine. Nucleic Acids Res. 49, D1197\u2013d1206. https:\/\/doi.org\/10.1093\/nar\/gkaa1063 (2021).","journal-title":"Nucleic Acids Res."},{"key":"87286_CR30","doi-asserted-by":"publisher","first-page":"D976","DOI":"10.1093\/nar\/gky987","volume":"47","author":"HY Xu","year":"2019","unstructured":"Xu, H. Y. et al. ETCM: an encyclopaedia of traditional Chinese medicine. Nucleic Acids Res. 47, D976\u2013d982. https:\/\/doi.org\/10.1093\/nar\/gky987 (2019).","journal-title":"Nucleic Acids Res."},{"key":"87286_CR31","doi-asserted-by":"publisher","first-page":"21146","DOI":"10.1038\/srep21146","volume":"6","author":"Z Liu","year":"2016","unstructured":"Liu, Z. et al. BATMAN-TCM: a Bioinformatics Analysis Tool for Molecular mechANism of Traditional Chinese Medicine. Sci. Rep. 6, 21146. https:\/\/doi.org\/10.1038\/srep21146 (2016).","journal-title":"Sci. Rep."},{"key":"87286_CR32","doi-asserted-by":"publisher","first-page":"D1055","DOI":"10.1093\/nar\/gkq1165","volume":"39","author":"H Ye","year":"2011","unstructured":"Ye, H. et al. HIT: linking herbal active ingredients to targets. Nucleic Acids Res. 39, D1055\u20131059. https:\/\/doi.org\/10.1093\/nar\/gkq1165 (2011).","journal-title":"Nucleic Acids Res."},{"key":"87286_CR33","doi-asserted-by":"publisher","first-page":"W356","DOI":"10.1093\/nar\/gkx374","volume":"45","author":"X Wang","year":"2017","unstructured":"Wang, X. et al. PharmMapper 2017 update: a web server for potential drug target identification with a comprehensive target pharmacophore database. Nucleic Acids Res. 45, W356\u2013w360. https:\/\/doi.org\/10.1093\/nar\/gkx374 (2017).","journal-title":"Nucleic Acids Res."},{"key":"87286_CR34","doi-asserted-by":"publisher","first-page":"A68","DOI":"10.5114\/wo.2014.47136","volume":"19","author":"K Tomczak","year":"2015","unstructured":"Tomczak, K., Czerwi\u0144ska, P. & Wiznerowicz, M. The Cancer Genome Atlas (TCGA): an immeasurable source of knowledge. Contemp. Oncol. (Pozn). 19, A68\u201377. https:\/\/doi.org\/10.5114\/wo.2014.47136 (2015).","journal-title":"Contemp. Oncol. (Pozn)"},{"key":"87286_CR35","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1038\/75556","volume":"25","author":"M Ashburner","year":"2000","unstructured":"Ashburner, M. et al. Gene ontology: tool for the unification of biology. The Gene Ontology Consortium. Nat. Genet. 25, 25\u201329. https:\/\/doi.org\/10.1038\/75556 (2000).","journal-title":"Nat. Genet."},{"key":"87286_CR36","doi-asserted-by":"publisher","first-page":"111760","DOI":"10.1016\/j.msec.2020.111760","volume":"120","author":"H Tang","year":"2021","unstructured":"Tang, H., Hosein, A. & Mattioli-Belmonte, M. Traditional Chinese Medicine and orthopedic biomaterials: host of opportunities from herbal extracts. Mater. Sci. Eng. C Mater. Biol. Appl. 120, 111760. https:\/\/doi.org\/10.1016\/j.msec.2020.111760 (2021).","journal-title":"Mater. Sci. Eng. C Mater. Biol. Appl."},{"key":"87286_CR37","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1039\/d2tb00225f","volume":"10","author":"D Wei","year":"2022","unstructured":"Wei, D. et al. Nano-traditional Chinese medicine: a promising strategy and its recent advances. J. Mater. Chem. B. 10, 2973\u20132994. https:\/\/doi.org\/10.1039\/d2tb00225f (2022).","journal-title":"J. Mater. Chem. B"},{"key":"87286_CR38","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.1002\/cam4.2108","volume":"8","author":"Y Xiang","year":"2019","unstructured":"Xiang, Y., Guo, Z., Zhu, P., Chen, J. & Huang, Y. Traditional Chinese medicine as a cancer treatment: modern perspectives of ancient but advanced science. Cancer Med. 8, 1958\u20131975. https:\/\/doi.org\/10.1002\/cam4.2108 (2019).","journal-title":"Cancer Med."},{"key":"87286_CR39","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1038\/nrc2607","volume":"9","author":"JL Nitiss","year":"2009","unstructured":"Nitiss, J. L. & Targeting DNA topoisomerase II in cancer chemotherapy. Nat. Rev. Cancer. 9, 338\u2013350. https:\/\/doi.org\/10.1038\/nrc2607 (2009).","journal-title":"Nat. Rev. Cancer"},{"key":"87286_CR40","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1016\/j.chembiol.2010.04.012","volume":"17","author":"Y Pommier","year":"2010","unstructured":"Pommier, Y., Leo, E., Zhang, H. & Marchand, C. DNA topoisomerases and their poisoning by anticancer and antibacterial drugs. Chem. Biol. 17, 421\u2013433. https:\/\/doi.org\/10.1016\/j.chembiol.2010.04.012 (2010).","journal-title":"Chem. Biol."},{"key":"87286_CR41","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1016\/j.biopha.2011.09.002","volume":"66","author":"E Kaplan","year":"2012","unstructured":"Kaplan, E. & G\u00fcnd\u00fcz, U. Expression analysis of TOP2A, MSH2 and MLH1 genes in MCF7 cells at different levels of etoposide resistance. Biomed. Pharmacother. 66, 29\u201335. https:\/\/doi.org\/10.1016\/j.biopha.2011.09.002 (2012).","journal-title":"Biomed. Pharmacother"},{"key":"87286_CR42","doi-asserted-by":"publisher","first-page":"474","DOI":"10.5114\/aoms.2020.92572","volume":"17","author":"M Nico\u015b","year":"2021","unstructured":"Nico\u015b, M. et al. Effect of TOP2A and ERCC1 gene polymorphisms on the efficacy and toxicity of cisplatin and etoposide-based chemotherapy in small cell lung cancer patients. Arch. Med. Sci. 17, 474\u2013480. https:\/\/doi.org\/10.5114\/aoms.2020.92572 (2021).","journal-title":"Arch. Med. Sci."},{"key":"87286_CR43","first-page":"242","volume":"24","author":"PJ Ferguson","year":"1995","unstructured":"Ferguson, P. J. Mechanisms of resistance of human tumours to anticancer drugs of the platinum family: a review. J. Otolaryngol. 24, 242\u2013252 (1995).","journal-title":"J. Otolaryngol."},{"key":"87286_CR44","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/nrm831","volume":"3","author":"JC Wang","year":"2002","unstructured":"Wang, J. C. Cellular roles of DNA topoisomerases: a molecular perspective. Nat. Rev. Mol. Cell. Biol. 3, 430\u2013440. https:\/\/doi.org\/10.1038\/nrm831 (2002).","journal-title":"Nat. Rev. Mol. Cell. Biol."},{"key":"87286_CR45","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/32588","volume":"392","author":"J Banchereau","year":"1998","unstructured":"Banchereau, J. & Steinman, R. M. Dendritic cells and the control of immunity. Nature 392, 245\u2013252. https:\/\/doi.org\/10.1038\/32588 (1998).","journal-title":"Nature"},{"key":"87286_CR46","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1038\/s41568-021-00347-z","volume":"21","author":"KJ Hiam-Galvez","year":"2021","unstructured":"Hiam-Galvez, K. J., Allen, B. M. & Spitzer, M. H. Systemic immunity in cancer. Nat. Rev. Cancer. 21, 345\u2013359. https:\/\/doi.org\/10.1038\/s41568-021-00347-z (2021).","journal-title":"Nat. Rev. Cancer"},{"key":"87286_CR47","doi-asserted-by":"publisher","unstructured":"Havasi, A., Cainap, S. S., Havasi, A. T. & Cainap, C. Ovarian Cancer-insights into Platinum Resistance and overcoming it. Med. (Kaunas). 59 https:\/\/doi.org\/10.3390\/medicina59030544 (2023).","DOI":"10.3390\/medicina59030544"},{"key":"87286_CR48","doi-asserted-by":"publisher","first-page":"436","DOI":"10.1038\/nature07205","volume":"454","author":"A Mantovani","year":"2008","unstructured":"Mantovani, A., Allavena, P., Sica, A. & Balkwill, F. Cancer-related inflammation. Nature 454, 436\u2013444. https:\/\/doi.org\/10.1038\/nature07205 (2008).","journal-title":"Nature"},{"key":"87286_CR49","doi-asserted-by":"publisher","unstructured":"Richardson, J. R., Sch\u00f6llhorn, A., Gouttefangeas, C. & Schuhmacher, J. CD4\u2009+\u2009T cells: Multitasking cells in the duty of Cancer Immunotherapy. Cancers (Basel). 13. https:\/\/doi.org\/10.3390\/cancers13040596 (2021).","DOI":"10.3390\/cancers13040596"},{"key":"87286_CR50","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1023\/a:1008329910362","volume":"10","author":"D Rayson","year":"1999","unstructured":"Rayson, D., Adjei, A. A., Suman, V. J., Wold, L. E. & Ingle, J. N. Metaplastic breast cancer: prognosis and response to systemic therapy. Ann. Oncol. 10, 413\u2013419. https:\/\/doi.org\/10.1023\/a:1008329910362 (1999).","journal-title":"Ann. Oncol."},{"key":"87286_CR51","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1038\/nature10983","volume":"486","author":"C Curtis","year":"2012","unstructured":"Curtis, C. et al. The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroups. Nature 486, 346\u2013352. https:\/\/doi.org\/10.1038\/nature10983 (2012).","journal-title":"Nature"},{"key":"87286_CR52","doi-asserted-by":"publisher","first-page":"e0157368","DOI":"10.1371\/journal.pone.0157368","volume":"11","author":"BD Lehmann","year":"2016","unstructured":"Lehmann, B. D. et al. Refinement of Triple-negative breast Cancer Molecular subtypes: implications for Neoadjuvant Chemotherapy Selection. PLoS One. 11, e0157368. https:\/\/doi.org\/10.1371\/journal.pone.0157368 (2016).","journal-title":"PLoS One"},{"key":"87286_CR53","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1146\/annurev-pathol-042420-093238","volume":"17","author":"F Derakhshan","year":"2022","unstructured":"Derakhshan, F. & Reis-Filho, J. S. Pathogenesis of Triple-negative breast Cancer. Annu. Rev. Pathol. 17, 181\u2013204. https:\/\/doi.org\/10.1146\/annurev-pathol-042420-093238 (2022).","journal-title":"Annu. Rev. Pathol."},{"key":"87286_CR54","doi-asserted-by":"publisher","first-page":"59","DOI":"10.5152\/tjbh.2015.1669","volume":"11","author":"N Eliyatk\u0131n","year":"2015","unstructured":"Eliyatk\u0131n, N., Yal\u00e7\u0131n, E., Zengel, B., Akta\u015f, S. & Vardar, E. Molecular classification of breast carcinoma: from traditional, old-fashioned way to a New Age, and a New Way. J. Breast Health. 11, 59\u201366. https:\/\/doi.org\/10.5152\/tjbh.2015.1669 (2015).","journal-title":"J. Breast Health"},{"key":"87286_CR55","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1002\/ps.2180","volume":"67","author":"SS Chu","year":"2011","unstructured":"Chu, S. S., Jiang, G. H. & Liu, Z. L. Insecticidal compounds from the essential oil of Chinese medicinal herb atractylodes chinensis. Pest Manag Sci. 67, 1253\u20131257. https:\/\/doi.org\/10.1002\/ps.2180 (2011).","journal-title":"Pest Manag Sci."},{"key":"87286_CR56","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1186\/s13058-020-01353-z","volume":"22","author":"TP Reddy","year":"2020","unstructured":"Reddy, T. P. et al. A comprehensive overview of metaplastic breast cancer: clinical features and molecular aberrations. Breast Cancer Res. 22, 121. https:\/\/doi.org\/10.1186\/s13058-020-01353-z (2020).","journal-title":"Breast Cancer Res."}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-87286-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-87286-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-87286-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T12:12:58Z","timestamp":1737547978000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-87286-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,22]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["87286"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-87286-z","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-5242698\/v1","asserted-by":"object"}]},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,22]]},"assertion":[{"value":"11 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 January 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"2856"}}